中华胰腺病杂志
中華胰腺病雜誌
중화이선병잡지
CHINESE JOURNAL OF PANCREATOLOGY
2012年
2期
75-78
,共4页
肖明兵%谢玲%倪温慨%陈不尤%陆翠华%李小彦%江枫%倪润洲
肖明兵%謝玲%倪溫慨%陳不尤%陸翠華%李小彥%江楓%倪潤洲
초명병%사령%예온개%진불우%륙취화%리소언%강풍%예윤주
胰腺肿瘤%半乳糖凝集素3%时间分解免疫荧光测定%血清
胰腺腫瘤%半乳糖凝集素3%時間分解免疫熒光測定%血清
이선종류%반유당응집소3%시간분해면역형광측정%혈청
Pancreatic neoplasms%Galectin-3%Time-resolved fluoroimmunoassay%Serum
目的 运用时间分解免疫荧光(TRFIA)法检测血清半乳糖凝集素3(Galectin-3,Gal-3)水平,并探讨Gal-3对胰腺癌的诊断价值.方法 采用固相双抗体夹心法建立检测血清Gal-3的TRFIA,探讨最佳实验条件.在最适条件下检测胰腺癌、胰腺良性占位、胰腺炎患者及健康对照者血清Gal-3水平,并联合检测血清CEA及CA19-9水平.结果 TRFIA法检测血清Gal-3的线性为0～100μg/L,批内变异系数(CV)≤6.45％,批间CV≤8.68％,平均回收率为106.6％.胰腺癌患者血清Gal-3水平为4.93(0.85～23.80) μg/L,明显高于胰腺良性占位者的2.83(2.17～4.06) μg/L、胰腺炎患者的2.62(0.55 ～9.76) μg/L和健康者的1.88(0.59 ～ 3.94) μg/L(P值均＜0.05).以3.77 μg/L为界,其诊断胰腺癌的敏感性为75.5％,特异性达90.9％.Gal-3与CEA及CA19-9水平均无相关性(r=0.1321,P=0.3761；r =0.0920,P=0.5384),Gal-3联合CEA或CA19-9检测,对胰腺癌的诊断敏感性可提高到92％.结论 TRFIA法检测血清Gal-3具有较好的敏感性和稳定性；Gal-3有望成为新的胰腺癌标记物.
目的 運用時間分解免疫熒光(TRFIA)法檢測血清半乳糖凝集素3(Galectin-3,Gal-3)水平,併探討Gal-3對胰腺癌的診斷價值.方法 採用固相雙抗體夾心法建立檢測血清Gal-3的TRFIA,探討最佳實驗條件.在最適條件下檢測胰腺癌、胰腺良性佔位、胰腺炎患者及健康對照者血清Gal-3水平,併聯閤檢測血清CEA及CA19-9水平.結果 TRFIA法檢測血清Gal-3的線性為0～100μg/L,批內變異繫數(CV)≤6.45％,批間CV≤8.68％,平均迴收率為106.6％.胰腺癌患者血清Gal-3水平為4.93(0.85～23.80) μg/L,明顯高于胰腺良性佔位者的2.83(2.17～4.06) μg/L、胰腺炎患者的2.62(0.55 ～9.76) μg/L和健康者的1.88(0.59 ～ 3.94) μg/L(P值均＜0.05).以3.77 μg/L為界,其診斷胰腺癌的敏感性為75.5％,特異性達90.9％.Gal-3與CEA及CA19-9水平均無相關性(r=0.1321,P=0.3761；r =0.0920,P=0.5384),Gal-3聯閤CEA或CA19-9檢測,對胰腺癌的診斷敏感性可提高到92％.結論 TRFIA法檢測血清Gal-3具有較好的敏感性和穩定性；Gal-3有望成為新的胰腺癌標記物.
목적 운용시간분해면역형광(TRFIA)법검측혈청반유당응집소3(Galectin-3,Gal-3)수평,병탐토Gal-3대이선암적진단개치.방법 채용고상쌍항체협심법건립검측혈청Gal-3적TRFIA,탐토최가실험조건.재최괄조건하검측이선암、이선량성점위、이선염환자급건강대조자혈청Gal-3수평,병연합검측혈청CEA급CA19-9수평.결과 TRFIA법검측혈청Gal-3적선성위0～100μg/L,비내변이계수(CV)≤6.45％,비간CV≤8.68％,평균회수솔위106.6％.이선암환자혈청Gal-3수평위4.93(0.85～23.80) μg/L,명현고우이선량성점위자적2.83(2.17～4.06) μg/L、이선염환자적2.62(0.55 ～9.76) μg/L화건강자적1.88(0.59 ～ 3.94) μg/L(P치균＜0.05).이3.77 μg/L위계,기진단이선암적민감성위75.5％,특이성체90.9％.Gal-3여CEA급CA19-9수평균무상관성(r=0.1321,P=0.3761；r =0.0920,P=0.5384),Gal-3연합CEA혹CA19-9검측,대이선암적진단민감성가제고도92％.결론 TRFIA법검측혈청Gal-3구유교호적민감성화은정성；Gal-3유망성위신적이선암표기물.
Objective To establish the time-resolved fluoroimmunoassay (TRFIA) method for the detection of serum galectin-3 and investigate the clinical value of serum galectin-3 for the diagnosis of pancreas cancer.Methods Monoclonal anti-human galectin - 3 antibody and biotinylated polyclonal antibody were used to establish the sandwich TRFIA for detection of serum galectin-3.The optimal experimental condition was studied.Serum levels of galectin-3,CEA and CA19-9 in the patients with pancreatic cancer,benign pancreatic mass,pancreatitis,and healthy controls were measured.The diagnostic value of serum galectin-3,CEA and CA19-9 for pancreas cancer was studied.Results The linearity of the TRFIA for detection of serum galectin3 tanged between 0 to 100 μg/L.The within-run CV and between-run CV were ≤6.45％ and ≤8.68％,respectively,and the average recovery was 106.6％.The level of serum galectin-3 was 4.93 ( 0.85 ～ 23.80) μg/L in pancreatic cancer group,which were significantly higher than those in benign pancreatic mass [2.83 ( 2.17 ～ 4.06) μg/L ],pancreatitis [ 2.62 (0.55 ～ 9.76 ) μg/L ],and healthy controls group [ 1.88 ( 0.59 ～ 3.94) μg/L] (P ＜0.05).By using 3.77 μg/L as the cut-off point,the smsitivity,specificity for the diagnosis of pancreatic cancer was 75.5％ and 90.9％.The levels of Gal 3 and CEA,CA19-9 was not correlated ( r =0.1321,P =0.3761 ; r =0.0920,P =0.5384).Combined determination of galactin-3 and CEA,CA19-9 levels could increase the diagnostic sensitivity to 92％.Conclusions TRFIA method for the detection of galactin-3 is sensitive and stable.Galectin-3 could be a potentially novel serum tumor marker of pancreatic cancer.
